News
Chasing rivals, AbbVie files migraine prevention drug atogep...
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their rece
